Related Experiment Video
Updated: Jul 13, 2025
10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
1.4K
Therapeutic strategies for glaucoma and optic neuropathies
Jung Lo1, Kamakshi Mehta2, Armaan Dhillon3
1Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
Molecular Aspects of Medicine
|October 15, 2023
Summary
Glaucoma treatments aim to lower intraocular pressure (IOP) but do not restore vision. Emerging therapies like gene therapy and stem cell treatments show promise for retinal ganglion cell (RGC) regeneration.
Area of Science:
- Ophthalmology
- Neuroscience
- Regenerative Medicine
Background:
- Glaucoma is a leading cause of irreversible vision loss due to retinal ganglion cell (RGC) and optic nerve degeneration.
- Elevated intraocular pressure (IOP) is a primary risk factor, but glaucoma can also occur with normal IOP.
- Current treatments focus on lowering IOP to slow disease progression, not on vision restoration.
Purpose of the Study:
- To review current advancements in understanding RGC development and regeneration.
- To explore the potential of gene therapy and stem cell transplantation for glaucoma treatment.
- To discuss future perspectives and challenges in RGC-based glaucoma therapies.
Main Methods:
- Literature review of recent research on RGC development, optic nerve regeneration, and stem cell differentiation.
- Analysis of current pharmacological and surgical interventions for glaucoma.
- Evaluation of emerging therapeutic strategies including gene therapy and stem cell transplantation.
Main Results:
- Pharmacotherapy and minimally invasive glaucoma surgery (MIGS) offer improved IOP management but do not reverse vision loss.
- Adeno-associated virus gene transduction and stem cell-based RGC replacement therapy present promising avenues for optic nerve repair.
- Further research into RGC developmental mechanisms is crucial for optimizing stem cell differentiation and gene therapy targets.
Conclusions:
- Existing glaucoma treatments manage IOP but do not restore lost vision.
- Gene therapy and stem cell transplantation hold significant potential for treating glaucoma by regenerating RGCs and optic nerve fibers.
- Continued investigation into RGC development and differentiation is essential for advancing regenerative therapies for glaucoma.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
471
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
471
01:28Angle Closure Glaucoma: Treatment
540
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
540
01:25Glaucoma: Overview
600
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
600
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
772
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
772
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
01:26Cholinergic Antagonists: Therapeutic Uses
758
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
758